PPCB (NASDAQ:PPCB – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports.
PPCB Trading Up 8.3%
PPCB stock opened at $0.24 on Wednesday. The company has a market capitalization of $3.59 million, a P/E ratio of -0.01 and a beta of 3.66. PPCB has a 12-month low of $0.16 and a 12-month high of $11.00.
Analysts Set New Price Targets
Separately, Weiss Ratings initiated coverage on PPCB in a report on Wednesday, January 14th. They issued a “sell (e-)” rating on the stock. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.
About PPCB
Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.
Read More
- Five stocks we like better than PPCB
- Energy Security Is Now National Security – Positioning Is Happening Now
- Gold Is About to Do Something It Hasn’t in 90 Years
- 3 Signs You May Want to Switch Financial Advisors
- ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!
- Why Q4 Could Destroy Your Wealth
Receive News & Ratings for PPCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPCB and related companies with MarketBeat.com's FREE daily email newsletter.
